Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurosense Therapeutics Ltd. ( (NRSN) ) has shared an update.
NeuroSense Therapeutics Ltd. has announced a Special Meeting of Shareholders scheduled for December 30, 2025, to discuss and vote on the approval of restricted share grants to non-management directors and the CEO, Alon Ben-Noon. These grants are intended as equity compensation to maintain financial flexibility and align management interests with those of shareholders. The Board of Directors unanimously recommends voting in favor of these proposals, which are seen as crucial for the company’s strategic financial management.
The most recent analyst rating on (NRSN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases. The company is based in Herzliya, Israel, and is engaged in the research and development of innovative therapies targeting various neurological conditions.
Average Trading Volume: 603,190
Technical Sentiment Signal: Sell
Current Market Cap: $26.82M
For a thorough assessment of NRSN stock, go to TipRanks’ Stock Analysis page.